Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

GlobeNewswire April 2, 2018

Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

Marketwired March 14, 2018

Acasti Pharma Reports Third Quarter FY 2018 Financial Results

Marketwired February 13, 2018

Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

MarketWire Canada January 22, 2018

Acasti Pharma Announces Change to Board of Directors

Marketwired January 16, 2018

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

Marketwired January 8, 2018

Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada

MarketWire Canada January 4, 2018

Dawson James Securities Announces Closing of US $10 Million Firm Commitment Offering of Common Shares and Warrants for Acasti Pharma Inc.

Accesswire January 2, 2018

Acasti Pharma to Present at Biotech Showcase Conference

MarketWire Canada January 2, 2018

Acasti Pharma Announces Closing of US$10 Million Firm Commitment Offering of Common Shares and Warrants

Marketwired December 27, 2017

Acasti Pharma Announces Pricing of US$10 Million Offering of Common Shares and Warrants

MarketWire Canada December 21, 2017

IIROC Trading Resumption - ACST

Canada NewsWire November 22, 2017

IIROC Trade Resumption - Acasti Pharma Inc.

Newsfile November 22, 2017

Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company

MarketWire Canada November 22, 2017

IIROC Trading Halt - ACST

Canada NewsWire November 20, 2017

IIROC Trade Halt - Acasti Pharma Inc.

Newsfile November 20, 2017

Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

Marketwired November 20, 2017

Acasti Pharma Reports Second Quarter FY 2018 Financial Results

Marketwired November 13, 2017

Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program

Marketwired November 7, 2017

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

Marketwired October 4, 2017